Valuation: UCB

Market Cap 40.88B 46.58B 38.61B 35.18B 65.86B 4,465B 66.33B 462B 179B 2,281B 175B 171B 7,331B P/E 2026 *
21.4x
P/E 2027 * 17.9x
Enterprise Value 41.28B 47.04B 38.98B 35.53B 66.5B 4,508B 66.98B 467B 181B 2,303B 177B 173B 7,402B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.07x
Free-Float
61.59%
Yield 2026 *
0.68%
Yield 2027 * 0.7%
1 day-3.37%
1 week-5.93%
Current month-6.07%
1 month-11.85%
3 months-20.58%
6 months-21.28%
Current year-19.73%
1 week 230.16
Extreme 230.16
254.09
1 month 228.94
Extreme 228.94
268.09
Current year 228.94
Extreme 228.94
345.39
1 year 228.94
Extreme 228.94
345.39
3 years 69.7
Extreme 69.7
345.39
5 years 68.3
Extreme 68.301062
345.39
10 years 58.42
Extreme 58.42
345.39
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-31
Director of Finance/CFO 60 2020-06-30
Chief Tech/Sci/R&D Officer 59 2024-04-30
Director TitleAgeSince
Director/Board Member 55 2011-12-31
Director/Board Member 67 2014-12-31
Director/Board Member 56 2014-04-23
Change 5-day change 1-year change 3-year change Capi.($)
-3.37%-5.93% - - 45.93B
-1.00%+0.41%+41.86%-5.58% 79.49B
+2.08%+29.11%+708.13%+102.59% 77.78B
-1.21%+0.77%-10.63%-30.06% 60.16B
-1.80%-2.29%-13.07%+28.02% 46.14B
+1.18%+3.03%+9.11%+169.01% 45.93B
+0.55%+5.61%+67.76%-10.75% 33.45B
-0.44%-1.13%+51.71%+110.88% 25.22B
-0.10%+3.21%+4.89%+155.64% 22.15B
+0.05%-2.42%+57.59%+97.38% 15.25B
Average -0.66%+4.15%+101.93%+68.57% 45.06B
Weighted average by Cap. -0.81%+6.41%+153.21%+54.62%

Financials

2026 *2027 *
Net sales 8.68B 9.89B 8.2B 7.47B 13.99B 948B 14.09B 98.13B 38.01B 484B 37.15B 36.35B 1,557B 9.62B 10.97B 9.09B 8.28B 15.5B 1,051B 15.61B 109B 42.12B 537B 41.17B 40.28B 1,726B
Net income 1.93B 2.2B 1.82B 1.66B 3.11B 211B 3.13B 21.79B 8.44B 108B 8.25B 8.07B 346B 2.3B 2.62B 2.17B 1.98B 3.7B 251B 3.73B 25.95B 10.05B 128B 9.83B 9.61B 412B
Net Debt 399M 455M 377M 343M 643M 43.58B 647M 4.51B 1.75B 22.27B 1.71B 1.67B 71.56B -1.73B -1.97B -1.63B -1.49B -2.78B -189B -2.8B -19.52B -7.56B -96.36B -7.39B -7.23B -310B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
26-09-25 US$235.66 -3.37% 34
26-09-24 US$243.88 +3.12% 543
26-09-22 US$236.49 +1.12% 379
26-09-21 US$233.86 -6.65% 429
26-09-18 US$250.52 +1.37% 31
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
214.40EUR
Average target price
285.00EUR
Spread / Average Target
+32.93%

Quarterly revenue - Rate of surprise